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Abstract
A growing body of evidence demonstrates a correlation between Th2 cytokines and the development of focal and
segmental glomerulosclerosis (FSGS). Therefore, we hypothesized that GSL-1, a monoglycosylceramide from Sphingomonas
ssp. with pro-Th1 activity on invariant Natural Killer T (iNKT) lymphocytes, could counterbalance the Th2 profile and
modulate glomerulosclerosis. Using an adriamycin(ADM)-based model of FSGS, we found that BALB/c mice presented
albuminuria and glomerular degeneration in association with a Th2-like pro-fibrogenic profile; these mice also expressed a
combination of inflammatory cytokines, such as IL-4, IL-1a, IL-1b, IL-17, TNF-a, and chemokines, such as RANTES and eotaxin.
In addition, we observed a decrease in the mRNA levels of GD3 synthase, the enzyme responsible for GD3 metabolism, a
glycolipid associated with podocyte physiology. GSL-1 treatment inhibited ADM-induced renal dysfunction and preserved
kidney architecture, a phenomenon associated with the induction of a Th1-like response, increased levels of GD3 synthase
transcripts and inhibition of pro-fibrotic transcripts and inflammatory cytokines. TGF-b analysis revealed increased levels of
circulating protein and tissue transcripts in both ADM- and GSL-1-treated mice, suggesting that TGF-b could be associated
with both FSGS pathology and iNKT-mediated immunosuppression; therefore, we analyzed the kidney expression of
phosphorylated SMAD2/3 and SMAD7 proteins, molecules associated with the deleterious and protective effects of TGF-b,
respectively. We found high levels of phosphoSMAD2/3 in ADM mice in contrast to the GSL-1 treated group in which
SMAD7 expression increased. These data suggest that GSL-1 treatment modulates the downstream signaling of TGF-b
through a renoprotective pathway. Finally, GSL-1 treatment at day 4, a period when proteinuria was already established,
was still able to improve renal function, preserve renal structure and inhibit fibrogenic transcripts. In conclusion, our work
demonstrates that the iNKT agonist GSL-1 modulates the pathogenesis of ADM-induced glomerulosclerosis and may
provide an alternative approach to disease management.
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Introduction
Focal and segmental glomerulosclerosis (FSGS) is a growing
cause of adult nephrotic syndrome and chronic kidney disease.
Although FSGS presents diverse histological patterns and
etiological associations, podocyte injury is a common denominator
[1]. The immunological mechanisms involved in the pathogenesis
of FSGS are not fully understood, but various studies demonstrate
an association between a Th2-like profile and disease develop-
ment. Yap and colleagues were the first to demonstrate a
correlation between increased IL-13 mRNA expression and
idiopathic nephrotic syndrome (INS) during childhood; because
FSGS is one of the most common causes of INS, it was considered
an indication of the association between Th2 cytokines and FSGS
[2]. In the spontaneous FSGS Buffalo/Mna rat model, Le Berre
and colleagues found an early imbalance in Th1/Th2 cytokines
due to a T-cell infiltrate with a predominant Th2 profile, which in
turn down-regulated Th1 responses [3]. Consistent with these
results, Lai and colleagues demonstrated that IL-13 over-
expression induced minimum change-like nephropathy, a phe-
nomenon associated with podocyte structural changes and
increased expression of IL-4Ra and IL-13Ra2 in the glomeruli
[4].
Combined, these previous studies support a correlation between
Th2 cytokines and the development of FSGS. Because of the
antagonism between Th1 and Th2 cytokines, we hypothesized
that the polarization of immune responses toward a Th1 profile
could inhibit or even modulate the pathogenesis of FSGS. In this
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(iNKT) by their agonist a-galactosylceramide (a-GaCer) or
analogs has been shown to increase Th1-mediated responses, a
property that has been used successfully to modulate Th2-
mediated diseases, such as asthma [5,6,7,8].
iNKT cells are non-conventional lymphocytes that can
modulate the outcome of different immune-mediated diseases
through the prompt secretion of different cytokines upon TCR
stimulation [9]. A characteristic feature of iNKT cells is their
selectivity for glycolipid antigens presented by the nonpolymorphic
MHC class I-like molecule CD1d, which has been used to
modulate different immune responses by exogenous agonists
[10,11,12]. We chose to study the effect of GSL-1, a mono-
glycosylceramide obtained from Sphingomonas ssp. with a pro-Th1
nature, on FSGS pathogenesis [13]. To this end, we used an
experimental model that is based on the susceptibility of podocytes
to the cytotoxic effects of doxorubicin hydrochloride, also known
as adriamycin (ADM) [14].
ADM-induced FSGS not only has an immune system-
dependent component but is also a reliable mimetic of the human
disease [15,16]. Although the immune component is not fully
understood, Th2-prone strains, such as BALB/c mice, are well
known to be more susceptible to ADM injury, corroborating the
idea that FSGS is a Th2-associated disease. Therefore, ADM-
FSGS is a useful model to both reproduce the disease and study
the effects of Th1 polarization on disease pathogenesis.
In this study, we demonstrate that GSL-1 treatment modulates
the development of ADM-induced FSGS in an iNKT-dependent
manner. A Th1-polarization, increased mRNA for enzymes
associated with ganglioside metabolism, and the modulation of
proteins involved with the regulation of TGF-b downstream
signaling were observed in this model.
Results
GSL-1 treatment inhibits ADM-induced proteinuria and
albuminuria
We first tested the effect of GSL-1 treatment on the renal failure
induced by ADM administration. BALB/c mice, aged 8 to 10
weeks, were injected at day 0 with ADM (10 mg/Kg) or ADM
plus GSL-1 (5 mg/animal). Figure 1A demonstrates that ADM
mice lost body weight in a time-dependent manner, likely as a
result of ADM-induced nephropathy. Consistent with this result,
the proteinuria/creatininuria ratio at day 7 was significantly
elevated in the ADM group compared with the control mice,
indicating impaired renal function (Figure 1B). In contrast, GSL-1-
treated mice gained body weight, as did the control animals,
suggesting that GSL-1 administration exerts a protective effect on
ADM-induced disease. In fact, the proteinuria levels found in
ADM+GSL-1 mice were comparable to that of the control group,
corroborating the renoprotective effect of GSL-1 treatment. The
total proteinuria/creatininuria ratio can be a marker for renal
function but is not a reliable indicator of glomerular alterations. In
contrast, albumin is a high molecular weight protein that is not
found in urine, and therefore, an increase in albumin levels reflects
a loss of the glomerular filtration barrier (GFB) due to podocyte
injury. Therefore, we measured the albuminuria/creatininuria
ratio to better characterize the extent of podocyte injury.
Consistent with data from Figure 1B, ADM mice showed
increased albuminuria compared with control and ADM+GSL-1
mice, supporting the idea that GSL-1 treatment protected
podocytes from ADM cytotoxicity and consequently preserved
the GFB (Figure 1C).
To better address the relationship between the renoprotective
effects of GSL-1 treatment and iNKT activation, we took
advantage of the BALB/c iNKT-deficient (Jalpha18
2/2) strain
[17]. As in BALB/c WT mice, ADM administration in
Jalpha18
2/2 animals resulted in a time-dependent loss of renal
function, illustrated by the increase in the proteinuria/creatini-
nuria ratio (Figure 1D). The glomerular damage was represented
by the elevated levels of albuminuria found at day 28 post-ADM
(Figure 1E). In contrast with the WT mice, the treatment of
Jalpha18
2/2 mice with GSL-1 was unable to inhibit FSGS
development; therefore, our data demonstrate that the protective
effect of GSL-1 is iNKT-dependent, corroborating the specificity
of GSL-1 as an iNKT agonist.
GSL-1 treatment inhibits ADM-induced renal injury
To determine the extent of the renal tissue damage, we
performed histological analyses at day 7 post-ADM. Figure 2
demonstrates that ADM injection resulted in alterations of renal
tissue, inducing mesangial hypercellularity, signs of glomerular
sclerosis and tubular degeneration when compared with control
mice (Figures 2A to 2D, respectively). In contrast, GSL-1
treatment preserved renal architecture, corroborating the conser-
vation of renal function depicted in Figure 1.
GSL-1 treatment modulates the pro-Th2 milieu induced
by ADM and inhibits the expression of pro-fibrotic
transcripts
The qPCR analyses of renal tissue revealed that ADM injection
resulted in an early increase in the mRNA levels of the pro-Th2
transcription factor GATA3 along with transcripts for IL-4 and
IL-13, two cytokines extensively associated with Th2 responses
(Figures 3A to 3C, respectively) [18,19,20]. In contrast, GSL-1
treatment inhibited GATA3 and IL-4 mRNA expression, a
phenomenon associated with increased mRNA expression of T-
bet (T box expressed in T-cells), a pro-Th1-related transcription
factor, TNF-a, a classical type 1 cytokine and CXCL16, a
chemokine associated with iNKT-mediated Th1 responses
(Figures 3D to 3F, respectively) [21,22]. These data are consistent
with the idea that FSGS is associated with Th2 responses and
support the hypothesis that GSL-1 treatment promotes a pro-Th1
polarization of the immune system and thereby protects the
kidneys.
Because FSGS pathology can be associated with kidney fibrosis,
we decided to determine the mRNA expression of vimentin,
plasminogen activator inhibitor-1 (PAI-1) and TIMP-1 (tissue
inhibitor of metalloproteinase-1). Figure 4A demonstrates that
ADM mice showed increased levels of mRNA for vimentin, which
was diminished in the GSL-1 group. Consistent with these results,
we found that the induction of PAI-1 mRNA was inhibited in
GSL-1 treated mice compared with the ADM group (Figure 4B).
Finally, TIMP-1 transcript levels also increased in the ADM group
compared with control and ADM+GSL-1 mice (Figure 4C). The
mRNA levels of metalloproteinase 9 (MMP9) were slightly
increased in both ADM and ADM+GSL-1 animals when
compared with the control group (Figure 4D). The western blot
analysis of kidney tissue corroborated the MMP9 and PAI-1
transcript findings, also showing a significant increase in desmin in
ADM animals compared with both control and ADM+GSL-1
animals (Figure S1). This result corroborates previous findings
associating podocyte injury with desmin expression [23]. Taken
together, our data demonstrate that the renoprotective effect of
GSL-1 is associated with the inhibition of important fibrogenic-
Modulation of FSGS by NKT Agonist
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injury.
GSL-1 treatment inhibits the inflammatory context
induced by ADM
To better characterize the inflammatory environment associ-
ated with ADM-induced FSGS pathogenesis, we performed a
multiparameter analysis of inflammatory cytokines present in
kidney tissue. Figure 5 demonstrates increased levels of IL-4, IL-
1a,I L - 1 b, TNF-a, IL-12p40 and IL-17 in the ADM group
compared with the control animals; such increases were not
observed in GSL-1-treated mice (Figures 5A, 5B, 5C, 5D, 5E and
5F, respectively). In addition, we found high levels of RANTES
and eotaxin in ADM- but not in GSL-1-treated mice (Figures 5G
and H, respectively); eotaxin is a chemokine extensively
associated with Th2 inflammation [24]. These data demonstrate
that, together with a Th2-like profile, FSGS development is also
associated with cytokines from the innate and Th17 ‘‘arms’’ of
the immune response. Moreover, these results further demon-
strate the inhibitory effect of GSL-1 treatment on the inflamma-
Figure 1. GSL-1 treatment inhibits ADM-induced renal failure due to podocyte injury in an iNKT-dependent manner. BALB/c WT or
iNKT-deficient (Jalpha18
2/2) mice were injected at day 0 with 10 mg/kg of adriamycin (ADM) or treated concomitantly with ADM and 5 mg/mouse
GSL-1 (ADM+GSL-1). (A) As a result of ADM cytotoxicity, the mice lost body weight in a time-dependent fashion, in contrast to the control, untreated
mice, and the GSL-1-treated group. (B) The increased proteinuria/creatininuria found in the ADM group at day 7 post-ADM injection reflects impaired
renal function compared with the control and ADM+GSL-1 animals. These data indicate a renoprotective effect of GSL-1 treatment. (C) The
albuminuria levels found in ADM animals reflect the podocyte injury due to ADM cytotoxicity. In contrast, the albuminuria/creatininuria ratio in the
ADM+GSL-1 group was comparable to that in the control animals, indicating podocyte conservation. The GSL-1 treatment failed to protect
Jalpha18
2/2 mice from ADM-induced renal injury, showing that its renoprotective effect is iNKT-dependent (D and E). * p,0.05 vs. control; # p,0.05
vs. ADM.
doi:10.1371/journal.pone.0032454.g001
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effect.
GSL-1 treatment induces an alternative TGF-b signaling
pathway
Glomerulosclerosis pathogenesis has been extensively associated
with TGF-b synthesis and/or signaling; therefore, we decided to
determine the effect of GSL-1 on TGF-b production. Figure 6A
demonstrates that ADM injection increased the serum levels of
total TGF-b when compared with control mice, reinforcing the
idea that TGF-b overproduction is associated with glomeruloscle-
rosis [25]. Unexpectedly, we found that GSL-1 treatment further
elevated the serum levels of TGF-b. qPCR analysis of kidney tissue
revealed that the induction of TGF-b mRNA exactly reflected the
serum findings. The ADM group showed higher levels of TGF-b
transcripts than the control animals but lower than those found in
GSL-1 mice (Figure 6B). These data suggest that, in our model,
TGF-b could be associated with either a renoprotective or
deleterious effect depending on the context in which it is produced.
We have previously shown that a renoprotective TGF-b signal
was associated with iNKT cells and the induction of TGF-b-
induced gene (TGFBI/BIGH3) transcripts [26]. Further PCR
analysis revealed that only treatment with GSL-1 was able to
induce the transcription of TGFBI mRNA (Figure 6C), suggesting
that the activation of iNKT cells by pro-Th1 agonists induced an
immunological milieu that favors the renoprotective effect of TGF-
b. To better understand this phenomenon, we used western
blotting to analyze the protein expression of SMAD2/3 and
SMAD7, which have been extensively associated with TGF-b
signaling. Figure 6D shows that ADM injection was associated
with increased levels of phosphorylated SMAD2/3 protein,
whereas GSL-1 treatment induced a slight increase in the levels
of SMAD7 protein. These data reinforce the idea that the effect of
TGF-b is dependent on the immune context induced by ADM or
ADM+GSL-1 treatment.
GSL-1 treatment increases the levels of GM3 and GD3
ganglioside synthase transcripts
ADM-induced podocyte injury has been associated with
decreased levels of glomerular GD3 ganglioside, whereas iNKT
cell activation has been associated with the synthesis of glycolipids,
predominantly gangliosides [27,28]. Therefore, we determined the
mRNA expression of different classes of enzymes involved in
glycolipid metabolism. We found that ADM mice showed a
significant decrease in mRNA levels for GD3 synthase (ST8Sia1),
whereas GSL-1-treated mice showed increased expression of
Figure 2. GSL-1 treatment inhibits renal injury due to ADM cytotoxicity. BALB/c mice were injected at day 0 with 10 mg/kg of adriamycin
(ADM) or treated concomitantly with ADM and 5 mg/mouse GSL-1 (ADM+GSL-1). (A) Representative image of the renal alterations induced by ADM
administration (black arrow). Figures B to D show graphic representation of the mesangial hypercellularity, signs of glomerular sclerosis and tubular
degeneration induced by ADM administration. Figure 2 corroborates the renoprotective effect of GSL-1 treatment depicted in Figure 1. * p,0.05 vs.
control; # p,0.05 vs. ADM.
doi:10.1371/journal.pone.0032454.g002
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previous studies showing a correlation between GD3 gangliosides
and kidney physiology [29,30,31,32]. In addition, the expression
of GM3 gangliosides has been shown to be associated with
protection from ADM-cytotoxicity through the induction of the
anti-apoptotic protein Bcl-2 [33]. Although ADM administration
did not influence the levels of GM3 synthase (ST3Gal5)
transcripts, GSL-1 treatment induced a significant increase in
the mRNA levels of this enzyme (Figure 7B). Consistent with the
idea that GM3 could be associated with renoprotection through
the induction of Bcl-2, we detected increased levels of Bcl-2
transcripts in ADM+GSL-1 mice (Figure 7C). Taken together,
these data suggest that iNKT activation due to GSL-1 adminis-
tration induces endogenous glycolipids that can, in turn, protect
podocytes from ADM cytotoxicity.
GSL-1 treatment ameliorates ADM-induced FSGS
Finally, we decided to determine whether the renoprotective
effect of GSL-1 could be extended to the treatment of an ongoing
disease. Therefore, we initiated GSL-1 treatment at day 4 post-
ADM injection, a time point when proteinuria was already
elevated when compared with control animals. Figure 8A
demonstrates that the time-dependent loss of body weight induced
by ADM administration was reversed by GSL-1 treatment at day
4. This phenomenon was associated with the reversion of time-
dependent renal failure, indicated by a continuous increase in
proteinuria and albuminuria levels in the ADM mice (Figures 8B
and 8C, respectively). Figures 8D and 8E demonstrate that the
recovery of renal function was associated with kidney preservation.
The transcripts for vimentin, PAI-1 and TIMP-1 were also
elevated in the ADM group when compared with the GSL-1
treated mice. Moreover, MMP9 mRNA was not detected in
ADM+GSL-1 mice, suggesting that MMP9 transcription was
inhibited (Figure 8F). Therefore, our data demonstrate that GSL-1
administration during the early stage of disease can reverse its
pathogenesis.
Discussion
The mechanisms involved in FSGS pathogenesis are still not
understood, but different studies have demonstrated, in both
humans and experimental models, that this disease is associated
with increased levels of Th2 cytokines [2,3,4]. Therefore, we first
Figure 3. GSL-1 treatment modulates the ADM-induced Th2-like cytokine profile and induces a pro-Th1 environment. BALB/c mice
were injected at day 0 with 10 mg/kg of adriamycin (ADM) or treated concomitantly with ADM and 5 mg/mouse GSL-1 (ADM+GSL-1). The ADM mice
had increased levels of mRNA for the Th2-related transcription factor GATA3 (A), reflecting increased transcript levels for IL-4 (B) and IL-13 (C). In
contrast, GSL-1 treatment inhibited these transcripts in association with an increase in the levels of mRNA for T-bet (D), a transcription factor
associated with Th1 responses, TNFa (E) and the chemokine ligand CXCL16 (F). Thus, these data corroborate the idea that ADM-induced FSGS is
associated with a Th2-like profile that can be inhibited by GSL-1 treatment and the generation of a pro-Th1 environment. * p,0.05 vs. control;
# p,0.05 vs. ADM.
doi:10.1371/journal.pone.0032454.g003
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the Th2-like profile associated with FSGS and thereby modulate
disease pathology. In fact, GSL-1 treatment inhibited the
inflammatory context induced by ADM and preserved renal
function, even when administered after proteinuria had already
been established.
Regardless of the diverse etiology and histological variations of
FSGS, it is clear that podocyte injury plays a pivotal role in this
disease. To test the hypothesis that GSL-1 could inhibit Th2
responses and thereby modulate glomerulosclerosis, we used the
ADM-induced FSGS model, an experimental model based on
podocyte susceptibility to doxorubicin cytotoxicity. As discussed by
Lee and Harris, this susceptibility depends on the immunological
tendency of the strain, illustrated by the difference in susceptibility
between BALB/c and C57BL/6 mice, which are described as
Th2- and Th1-prone strains, respectively [34]. It is well
documented that BALB/c mice are more susceptible to ADM-
FSGS than any other strain, suggesting that the tendency to Th2
responses favors ADM-induced nephrology. We have shown here
that, together with a Th2-like profile represented by high levels of
GATA3, IL-4 and eotaxin, ADM-treated mice produced a mix of
inflammatory cytokines from both the innate and Th17 ‘‘arms’’ of
the immune system that were inhibited by GSL-1 treatment.
Therefore, our data indicate that the Th1/Th2 imbalance may be
simply one aspect of a more intricate mechanism of glomerular
injury.
Despite the association between Th2 cytokines and FSGS, the
mechanism involved in podocyte susceptibility to ADM cytotox-
icity is not fully understood. Holtho ¨fer et al. showed that podocyte
injury was associated with a decrease in glomerular disialoganglio-
sides (GD3) in a model of puromycin induced-FSGS [30]. Simons
et al. demonstrated that lipid rafts containing GD3 gangliosides
are involved in podocyte foot process effacement, indicating an
important role for raft components in both pathological and
physiological processes [32]. It has also been shown that the
expression of GM3, the GD3 precursor, inhibited ADM-induced
Lewis cell carcinoma death due to the induction of the anti-
apoptotic protein Bcl-2 [33]. Therefore, gangliosides can be
associated with both the conservation of podocyte structure and
resistance to ADM cytotoxicity. In this regard, we found that
ADM administration decreased the mRNA levels of GD3 synthase
(ST8Sia1) when compared with control mice, suggesting the
inhibition of its transcription. These data could reflect a decrease
in the presence of GD3 within rafts and thereby explain podocyte
injury. Consistent with this idea, GSL-1 treatment increased both
GD3 synthase and GM3 synthase transcripts in association with
an increase in the mRNA levels of the anti-apoptotic protein Bcl-2.
Therefore, our data suggest that iNKT activation induces the
metabolism of endogenous glycolipids that can promote either the
preservation of podocyte structure due to GD3 conservation or
resistance to ADM-induced cytotoxicity via the GM3/Bcl-2 axis.
The induction of endogenous gangliosides by GSL-1 treatment is
consistent with previous studies showing an association between
iNKT cell activation and glycolipid metabolism [27,35].
In addition to a Th2-like profile and changes in ganglioside
metabolism, the pathogenesis of glomerulosclerosis is also marked
by the presence of the fibrogenic cytokine TGF-b, which has been
implicated in podocyte apoptosis, proliferation, epithelial-to-
mesenchymal transition and glomerular matrix deposition
[23,36,37,38]. We demonstrated in an anti-glomerular basement
membrane model of glomerulonephritis that iNKT cells modulate
their pathogenesis through an alternative TGF-b signaling
pathway, indicating a renoprotective role for TGF-b-iNKT axis
and TGF-b-induced genes (TGFBI/BIGH3) [26]. Consistent with
these results, we found that iNKT activation through GSL-1
treatment increased the TGF-b protein levels in serum and the
expression of both TGF-b and TGFBI transcripts in kidney
compared with both the control and ADM groups. These data
corroborate the idea that the renoprotective effect of iNKT
activation is somehow associated with TGFBI expression and
suggest that TGF-b signaling differs between ADM and
ADM+GSL-1 animals. In fact, ADM administration resulted in
an increase in the expression of phosphorylated SMAD2/3,
whereas GSL-1 treatment augmented the levels of the inhibitory
SMAD7 protein.
The role of TGFBI protein in the kidney still remains unclear,
but TGFBI is part of the extracellular matrix and has been
implicated in the regeneration of renal proximal tubular epithelia,
consistent with a renoprotective function [39]. Regarding the
SMAD7 protein, Shiffer et al. suggested that it is activated during
podocyte injury to control TGF-b/SMAD signaling and restore
kidney physiology [40]. In the same context, Wang et al.
demonstrated that in response to latent TGF-b1 signaling,
SMAD7 inhibits NF-kB-driven inflammatory responses [41].
Figure 4. GSL-1 treatment inhibits the ADM-induced expres-
sion of fibrogenic mRNAs. BALB/c mice were injected at day 0 with
10 mg/kg of adriamycin (ADM) or treated concomitantly with ADM and
5 mg/mouse GSL-1 (ADM+GSL-1). (A) ADM mice presented increased
levels of vimentin compared with control mice; vimentin was
diminished in GSL-1-treated group. (B) The levels of PAI-1 transcripts
significantly increased in ADM mice, in contrast with ADM+GSL-1
animals, which had levels comparable to that of the control mice. (C)
TIMP-1 mRNA increased in the ADM group compared with the control
and ADM+GSL-1 mice (D) MMP9 transcripts were equally increased in
the ADM and ADM+GSL-1 groups compared with the control mice.
These data indicate the development of ADM-induced FSGS with renal
remodeling. * p,0.05 vs. control; # p,0.05 vs. ADM.
doi:10.1371/journal.pone.0032454.g004
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consistent with the ideas that this protein is associated with
podocyte and renal physiology and that GSL1 can modulate TGF-
b signaling.
In conclusion, our work demonstrates that FSGS pathogenesis is
regulated by an intricate network involving different inflammatory
cytokines and chemokines, glycolipid metabolism and TGF-b
signaling. We have also shown that pro-Th1 iNKT agonists can
modulate this network to maintain podocyte physiology, suggest-
ing a new approach to FSGS management.
Materials and Methods
Ethical Statements
The animals used in this work were housed in individual
standard cages and maintained on a 12-h light/dark cycle in a
temperature-controlled room at 21–23uC with free access to water
and food. All procedures were approved by the internal ethics
committee of the Federal University of Sa ˜o Paulo (1874/07).
Animals and treatments
Isogenic male Balb/c mice, aged 8–12 weeks (23–28 g), were
obtained from the Animal Care Facility at the Federal University
of Sa ˜o Paulo (UNIFESP). The BALB/c Jalpha18
2/2 mice were a
gift from Dr. Masaru Taniguchi at the RIKEN Research Center
for Allergy and Immunology (Japan) [17]. All animals were
housed in individual standard cages and had free access to food
and water. All procedures were previously reviewed and
approved by the internal ethics committee of the institution.
Focal segmental glomerulosclerosis was induced in mice using a
single tail-vein injection of 10 mg/kg adriamycin (Doxorubicin
hydrochloride, Pfizer, NY, USA); an equal volume of saline was
given to control mice [15,42,43]. GSL-1 (5 mg/animal i.v.) was
administered concomitantly with the ADM administration or
four days later. GSL-1 glycolipid was synthesized as previously
described [13].
Renal function
To evaluate the renal function of the mice, urine samples were
collected at different time points to quantify proteinuria and the
albuminuia:creatininuria ratio. All samples were analyzed using
commercially available colorimetric assays: Labtest (Minas Gerais,
Brazil) for creatinine measurements and SensiprotH (Minas Gerais,
Brazil) for protein measurements. To estimate the urinary albumin
concentration, 10 mL of urine (1 mg/mL), corrected for the
Figure 5. GSL-1 treatment inhibits the inflammatory context induced by ADM administration. BALB/c mice were injected at day 0 with
10 mg/kg of adriamycin (ADM) or treated concomitantly with ADM and 5 mg/mouse GSL-1 (ADM+GSL-1). ADM mice had increased levels of the
inflammatory cytokines IL-4, IL-1a, IL-1b, TNF-a, IL-12p40 and IL-17 compared with both the control and GSL-1-treated groups (A to F, respectively).
The administration of ADM also induced high levels of inflammatory chemokines, such as RANTES and eotaxin, which were inhibited by GSL-1
treatment (G and H, respectively). These data indicate an inhibitory effect for GSL-1 treatment, supporting its renoprotective effect. * p,0.05 vs.
control; # p,0.05 vs. ADM.
doi:10.1371/journal.pone.0032454.g005
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Coomassie stained. The densities of the bands present in the gel
were analyzed using the GeneSnap and Gene Tools software
(Syngene, UK).
Real-time PCR analysis
On the day of sacrifice, kidney samples were quickly frozen in
liquid nitrogen. Total RNA was isolated using the TRIzol Reagent
(Invitrogen, USA). First-strand cDNAs were synthesized using the
MML-V reverse transcriptase (Promega, USA). Real-time PCR
was performed using the TaqMan PCR assay and the following
probes: TNF-a, Mm00443258; PAI-1, Mm 01204469; vimentin,
Mm00801666; BCL-2, Mm 02528810; MMP9, Mm01240560
(Applied Biosystems, USA). For the analyses of IL-4, IL-13,
GATA3, T-bet, glycosyltransferases, TGF-b and TGFBI (BiGH3),
real-time PCR was performed using SYBR Green (Table 1)
(Applied Biosystems, USA). The cycling conditions used with the
Taqman and SYBR Green primers were as follows: 10 min at
95uC, followed by 45 cycles of 30 s at 95uC, 30 s at 60uC and 30 s
at 72uC. The relative quantification of mRNA levels was
performed using the comparative threshold cycle method (Applied
Biosystems, USA). Briefly, the target gene amount was normalized
to the endogenous reference gene (HPRT, SYBR Green), and
then normalized to a calibrator (control animals) using the formula
2
2DDCt. Thus, all data were expressed as an N-fold difference
related to the expression in the matched controls. Analyses were
performed using the Sequence Detection Software 1.9 (Applied
Biosystems, USA).
Renal histology analysis
On the day of sacrifice, kidneys were fixed in 10% neutral
formalin for 24 h and then embedded in paraffin. Sections (3 mm)
were stained with hematoxylin/eosin and analyzed using a
trinocular optical microscope (Olympus Corporation, Japan).
Glomerulosclerosis was evaluated based on the percentage of
glomeruli damaged [44]. Tubulointerstitial injury was defined as
tubular dilation and/or atrophy or characterized by interstitial
fibrosis, as previously described [45,46]. Tubular injury was scored
as follows: 0=changes in ,10% of the cortex; 1+=changes in up
to 25% of the cortex; 2+=changes in up to 50% of the cortex; and
3+=changes in .50% of the cortex sections.
TGFb-1 protein levels were measured by enzyme-linked
immunosorbent assay (ELISA).
TGFb-1 protein was assessed in kidney tissues lysed with RIPA
Buffer (25 mM TrisNHCl pH 7.6, 150 mM NaCl, 1% NP-40, 1%
sodium deoxycholate, 0.1% SDS) supplemented with a protease
inhibitor (Sigma Aldrich, USA). Total TGFb-1 protein was
measured using a TGFb-1 Emax immunoassay system (Promega,
USA) according to the manufacturer’s instructions. The results
were presented as pg of TGFb-1/mg of total protein measured
using the Bradford assay (Bio-Rad, USA).
Western blot analysis
Briefly, 100 mg of total protein from renal tissue were collected
and then diluted in sample buffer (Bio-Rad, USA) containing
20 mg/ml of 2-b- mercaptoethanol (Sigma, United States). The
samples were denatured for 5 min at 95uC and then separated on
a 10% polyacrylamide electrophoresis gel. Next, the proteins were
transferred onto a nitrocellulose membrane, blocked for an hour
with 5% albumin diluted in TBS-T solution and then incubated
with the primary antibody diluted in TBS. Finally, the membrane
was washed with TBS for an hour and incubated with the
secondary biotinylated antibody. The molecular masses of the
proteins were determined by comparison with the migration of
rainbow markers (Bio-Rad, USA). The following antibodies were
used for western blotting: phosphorylated SMAD2/3, SMAD7
and GAPDH (Santa Cruz Biotechnology Inc., USA) and MMP9,
PAI-1, Desmin and HPRT (Abcam, USA).
Statistical analysis
All data are presented as the mean 6 SEM. Different results
among the groups were compared by ANOVA. The threshold for
significance was established as p,0.05. All statistical analyses were
performed with the aid of GraphPad PRISM (Graphpad, USA).
Figure 6. GSL-1 treatment modulates TGF-b signaling. BALB/c
mice were injected at day 0 with 10 mg/kg of adriamycin (ADM) or
treated concomitantly with ADM and 5 mg/mouse GSL-1 (ADM+GSL-1).
(A) Total TGF-b protein increased in the serum of both the ADM and
ADM+GSL-1 groups compared with the control animals. (B) The
increase in TGF-b transcripts in kidney tissue reflected the serum
findings showing that the ADM and ADM+GSL-1 groups had higher
levels of this cytokine compared with the control mice. GSL-1 treatment
induced a more significant increase in serum TGFb and mRNA
transcripts compared with the ADM group; however, only ADM+GSL-
1 mice presented transcripts to the TGFBI/BIGH3 protein (C), indicating
that TGF-b production had a different effect in this group. This idea is
supported by the presence of phosphorylated SMAD2/3 in ADM mice,
whereas in the ADM+GSL-1 group, the expression of SMAD7 protein
increased (D). These data indicate that GSL-1 treatment modulated the
downstream cascade of TGF-b signaling. * p,0.05 vs. control; # p,0.05
vs. ADM.
doi:10.1371/journal.pone.0032454.g006
Modulation of FSGS by NKT Agonist
PLoS ONE | www.plosone.org 8 March 2012 | Volume 7 | Issue 3 | e32454Figure 7. GSL-1 treatment induces transcripts for GM3 and GD3 synthases and the anti-apoptotic protein Bcl-2. BALB/c mice were
injected at day 0 with 10 mg/kg of adriamycin (ADM) or treated concomitantly with ADM and 5 mg/mouse GSL-1 (ADM+GSL-1). (A) The ADM group
showed decreased levels of ST8Sia1, the enzyme responsible for the generation of GD3 gangliosides, molecules that have been associated with
podocyte physiology. In contrast, GSL-1 treatment increased the levels of this transcript compared with both control and ADM mice. (B) The levels of
mRNA for GM3 synthase (ST3Gal5) were not altered in the ADM group; however, they were significantly augmented after GSL-1 treatment. Because
GM3 gangliosides were associated with resistance to ADM-cytotoxicity due to Bcl-2 induction, we measured the mRNA levels of this protein in our
system. (C) Bcl-2 transcripts were not altered by ADM but increased in ADM+GSL-1 mice, indicating a relationship between increased ST3Galt5 and
Bcl-2 transcripts with renal protection from effects of ADM. * p,0.05 vs. control; # p,0.05 vs. ADM.
doi:10.1371/journal.pone.0032454.g007
Figure 8. GSL-1 treatment reversed the time-dependent ADM-induced renal failure. BALB/c mice were injected at day 0 with 10 mg/kg of
adriamycin (ADM) or treated with ADM and four days later with 5 mg/mouse GSL-1 (ADM+GSL-1). (A) The loss of body weight associated with ADM
injection was reversed after GSL-1 treatment. The time-dependent renal failure, characterized by increases in the proteinuria (B) and albuminuria (C)
ratios, was inhibited after GSL-1 treatment at day 4 post-ADM injection. This amelioration in renal function was associated with kidney preservation( D
and E) and the inhibition of transcripts for fibrogenic proteins (F). * p,0.05 vs. control; # p,0.05 vs. ADM.
doi:10.1371/journal.pone.0032454.g008
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Figure S1 GSL-1 treatment inhibits the expression of
fibrogenic proteins. BALB/c mice were injected at day 0 with
10 mg/kg of adriamycin (ADM) or treated concomitantly with
ADM and 5 mg/mouse GSL-1 (ADM+GSL-1). Consistent with
the transcript analysis of kidney tissue, ADM mice showed a slight
increase in the expression of PAI-1 protein (B), without significant
alteration in MMP9 protein levels (A), when compared with the
control and ADM+GSL-1 animals. In contrast, Desmin expression
significantly increased in ADM mice when compared with both
the control and GSL-1-treated groups (C). These data corroborate
our previous mRNA analysis and further demonstrate the
protective effect of GSL-1 treatment.
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